| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
|
Proc Natl Acad Sci U S A
|
2002
|
32.26
|
|
2
|
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
|
Blood
|
2010
|
4.51
|
|
3
|
Input subsidies to improve smallholder maize productivity in Malawi: toward an african green revolution.
|
PLoS Biol
|
2009
|
4.06
|
|
4
|
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
4.06
|
|
5
|
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
|
Blood
|
2007
|
2.91
|
|
6
|
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
|
Cancer
|
2004
|
2.78
|
|
7
|
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
|
J Clin Oncol
|
2006
|
2.22
|
|
8
|
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
|
Blood
|
2003
|
2.06
|
|
9
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
Blood
|
2004
|
2.03
|
|
10
|
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
|
Blood
|
2003
|
1.94
|
|
11
|
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
|
Blood
|
2007
|
1.87
|
|
12
|
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
|
Leuk Lymphoma
|
2014
|
1.77
|
|
13
|
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.
|
Leuk Lymphoma
|
2010
|
1.73
|
|
14
|
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
|
Blood
|
2003
|
1.72
|
|
15
|
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
|
Clin Cancer Res
|
2004
|
1.68
|
|
16
|
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
|
J Clin Oncol
|
2003
|
1.67
|
|
17
|
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
|
Cancer
|
2003
|
1.50
|
|
18
|
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
|
Leuk Res
|
2008
|
1.45
|
|
19
|
Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.
|
Leuk Res
|
2010
|
1.42
|
|
20
|
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.
|
Cancer
|
2011
|
1.42
|
|
21
|
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
|
Clin Cancer Res
|
2002
|
1.42
|
|
22
|
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
|
Cancer
|
2006
|
1.36
|
|
23
|
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
|
J Clin Oncol
|
2009
|
1.27
|
|
24
|
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
|
Cancer
|
2004
|
1.27
|
|
25
|
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.
|
Blood
|
2005
|
1.24
|
|
26
|
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.
|
J Infect
|
2002
|
1.23
|
|
27
|
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
|
Mol Cancer Ther
|
2006
|
1.20
|
|
28
|
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
|
Cancer
|
2008
|
1.18
|
|
29
|
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
|
Blood
|
2007
|
1.14
|
|
30
|
Concomitant ventral phalloplasty during penile implant surgery: a novel procedure that optimizes patient satisfaction and their perception of phallic length after penile implant surgery.
|
J Sex Med
|
2007
|
1.12
|
|
31
|
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.
|
Blood
|
2010
|
1.12
|
|
32
|
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
|
Blood
|
2011
|
1.11
|
|
33
|
Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
|
PLoS One
|
2010
|
1.07
|
|
34
|
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
|
Blood
|
2003
|
1.05
|
|
35
|
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
|
Haematologica
|
2007
|
1.02
|
|
36
|
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
|
Cancer
|
2005
|
1.01
|
|
37
|
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
|
Leuk Res
|
2006
|
0.98
|
|
38
|
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
|
Cancer
|
2003
|
0.98
|
|
39
|
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
|
Clin Cancer Res
|
2002
|
0.97
|
|
40
|
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
|
J Clin Invest
|
2016
|
0.96
|
|
41
|
Differences in CD33 intensity between various myeloid neoplasms.
|
Am J Clin Pathol
|
2002
|
0.96
|
|
42
|
The CD38 ectoenzyme family: advances in basic science and clinical practice.
|
Mol Med
|
2007
|
0.94
|
|
43
|
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.
|
Cancer
|
2009
|
0.94
|
|
44
|
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
|
Cancer
|
2006
|
0.94
|
|
45
|
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
|
Blood
|
2005
|
0.93
|
|
46
|
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
|
Clin Cancer Res
|
2009
|
0.93
|
|
47
|
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
|
Leuk Res
|
2006
|
0.92
|
|
48
|
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.
|
Cancer
|
2006
|
0.92
|
|
49
|
Pregnancy in a patient with hypereosinophilic syndrome.
|
Leuk Res
|
2008
|
0.92
|
|
50
|
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
|
Leuk Lymphoma
|
2006
|
0.90
|
|
51
|
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
Cancer
|
2002
|
0.87
|
|
52
|
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
|
Cancer
|
2003
|
0.85
|
|
53
|
Ventral phalloplasty.
|
Asian J Androl
|
2008
|
0.85
|
|
54
|
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.
|
Front Oncol
|
2013
|
0.85
|
|
55
|
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
|
Cancer
|
2008
|
0.85
|
|
56
|
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
|
Leuk Res
|
2002
|
0.84
|
|
57
|
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
|
Clin Cancer Res
|
2003
|
0.84
|
|
58
|
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
|
Cancer Biomark
|
2009
|
0.84
|
|
59
|
Mature T-cell leukemias.
|
Cancer
|
2005
|
0.83
|
|
60
|
The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease.
|
Cancer
|
2002
|
0.83
|
|
61
|
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
|
Cancer
|
2003
|
0.82
|
|
62
|
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
|
Br J Haematol
|
2002
|
0.82
|
|
63
|
Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.
|
Eur J Haematol
|
2003
|
0.82
|
|
64
|
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
|
Br J Haematol
|
2003
|
0.81
|
|
65
|
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
|
Blood
|
2006
|
0.81
|
|
66
|
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
|
Cancer
|
2003
|
0.81
|
|
67
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
J Clin Oncol
|
2009
|
0.81
|
|
68
|
Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.80
|
|
69
|
The significance of spliceosome mutations in chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2013
|
0.80
|
|
70
|
Forodesine: review of preclinical and clinical data.
|
Future Oncol
|
2010
|
0.80
|
|
71
|
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.
|
Leuk Res
|
2004
|
0.80
|
|
72
|
Aurora-A kinase nuclear expression in chronic lymphocytic leukemia.
|
Mod Pathol
|
2008
|
0.80
|
|
73
|
DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.
|
Leuk Lymphoma
|
2013
|
0.79
|
|
74
|
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2003
|
0.79
|
|
75
|
Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
|
Med Oncol
|
2002
|
0.79
|
|
76
|
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
|
Cancer
|
2007
|
0.78
|
|
77
|
T-cell prolymphocytic leukemia: a single-institution experience.
|
Clin Lymphoma Myeloma
|
2005
|
0.78
|
|
78
|
Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2013
|
0.78
|
|
79
|
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
|
Cancer Chemother Pharmacol
|
2002
|
0.78
|
|
80
|
Factors associated with interest in subspecialty training among neurology residents.
|
Teach Learn Med
|
2015
|
0.77
|
|
81
|
CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype.
|
Arch Pathol Lab Med
|
2003
|
0.77
|
|
82
|
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
|
Cancer
|
2003
|
0.76
|
|
83
|
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
|
Cancer
|
2014
|
0.76
|
|
84
|
Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease?
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.76
|
|
85
|
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
|
Cancer
|
2003
|
0.76
|
|
86
|
Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
87
|
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).
|
J Blood Med
|
2010
|
0.75
|
|
88
|
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
89
|
Factors influencing the desire to provide MS patient care in clinical practice among physiatrists.
|
NeuroRehabilitation
|
2016
|
0.75
|
|
90
|
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
|
Cancer
|
2003
|
0.75
|
|
91
|
Mayo Clinic office visit. Germs and you. An interview with Michael Keating, M.D.
|
Mayo Clin Womens Healthsource
|
2005
|
0.75
|
|
92
|
Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
|
Med Oncol
|
2002
|
0.75
|
|
93
|
Chronic lymphocytic leukemia presenting in association with aplastic anemia.
|
Am J Hematol
|
2002
|
0.75
|
|
94
|
557: USE OF A SCREENING TOOL FOR PALLIATIVE CARE IN THE MEDICAL INTENSIVE CARE UNIT.
|
Crit Care Med
|
2016
|
0.75
|
|
95
|
Nurses' Health Study: landmark study recruiting for third cohort.
|
Insight
|
2014
|
0.75
|